Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia

[1]  P. Sandercock,et al.  Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials , 2021, BMC Medical Research Methodology.

[2]  Hao Li,et al.  Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke , 2021, JAMA neurology.

[3]  C. Anderson,et al.  Brain imaging abnormalities and outcome after acute ischaemic stroke: the ENCHANTED trial , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[4]  S. Johnston,et al.  Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. , 2019, JAMA neurology.

[5]  S. Johnston,et al.  Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. , 2019, JAMA neurology.

[6]  S. Pocock,et al.  Baseline characteristics of the 3096 patients recruited into the ‘Triple Antiplatelets for Reducing Dependency after Ischemic Stroke’ trial , 2017, International journal of stroke : official journal of the International Stroke Society.

[7]  R. Sacco,et al.  The Intracranial-B2LEED3S Score and the Risk of Intracranial Hemorrhage in Ischemic Stroke Patients Under Antiplatelet Treatment , 2017, Cerebrovascular Diseases.

[8]  Michael J Pencina,et al.  Evaluating Discrimination of Risk Prediction Models: The C Statistic. , 2015, JAMA.

[9]  S. Pocock,et al.  Safety and efficacy of intensive vs. guideline antiplatelet therapy in high‐risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388) , 2015, International journal of stroke : official journal of the International Stroke Society.

[10]  S. Pocock,et al.  Statistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial , 2014, International journal of stroke : official journal of the International Stroke Society.

[11]  D. Leys,et al.  Assessment of Additional Endpoints for Trials in Acute Stroke – What, When, Where, in Who? , 2012, International journal of stroke : official journal of the International Stroke Society.

[12]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[13]  Deepak L. Bhatt,et al.  Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis , 2010, European heart journal.

[14]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[15]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[16]  R. Brooks.  EuroQol: the current state of play. , 1996, Health policy.

[17]  T. Tatemichi,et al.  The Telephone Interview for Cognitive Status (TICS): Reliability and validity in a stroke sample , 1994 .

[18]  W. Burke,et al.  Validation of a Telephone Version of the Mini‐Mental State Examination , 1992, Journal of the American Geriatrics Society.

[19]  W. Zung.  A SELF-RATING DEPRESSION SCALE. , 1965, Archives of general psychiatry.